CureVac

World Rank (Jan-05-2024)

8,888

Market Cap (Jan-05-2024)

0.945 Billion USD

World Rank (Jul-30-2023)

5,858

Market Cap (Jul-30-2023)

1.945 Billion USD

World Rank (Jan-07-2022)

2,943

Market Cap (Jan-07-2022)

5.739 Billion USD

World Rank (Jan-01-2021)

1,226

Market Cap (Jan-01-2021)

14.428 Billion USD

Company Rank in Country in 2023

Rank in Germany in July-2023 is 119

Headquarters Country

Germany

Nasdaq / NYSE Code

CVAC

Employee Count

500

Employee Count as of Date

As on 2020

World Region

Europe

World Subregion

Western Europe

Annual Revenue in USD

74 Million USD

Annual Operating Income in USD

-276 Million USD

Annual Net Income in USD

-275 Million USD

Annual Results for Period Ending

Dec-2022 ending year

Total Assets in USD

948 Million USD

Total Liabilities in USD

361 Million USD

Total Equity in USD

588 Million USD

Balance Sheet for Period Ending

Dec-2022 ending year

Business Sector

Company Website

Wikipedia

Yahoo

Yahoo @ Nasdaq

Company Profile

CureVac is the leading global Clinical Stage Biopharmaceutical company focused on the development of a completely new class of drugs based on the messenger RNA (mRNA). The headquarters is in Germany.

Annual Results Summary

CUREVAC - Yearly Revenue and Net Income - in Million EUR:

Year - Ending	Revenue	Operating Income	Net Income
Dec-2022	67	-250 (Loss)	-249 (Loss)
Dec-2021	102	-412 (Loss)	-411 (Loss)
Dec-2020	48,	-109 (Loss)	-129 (Loss)
Dec-2019	17	-99 (Loss)	-99 (Loss)
Dec-2018	12	-72 (Loss)	-71 (Loss)